留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压新进展

高璐阳 罗勤 赵智慧 赵青 柳志红

高璐阳, 罗勤, 赵智慧, 赵青, 柳志红. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压新进展[J]. 协和医学杂志, 2023, 14(5): 1060-1066. doi: 10.12290/xhyxzz.2023-0031
引用本文: 高璐阳, 罗勤, 赵智慧, 赵青, 柳志红. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压新进展[J]. 协和医学杂志, 2023, 14(5): 1060-1066. doi: 10.12290/xhyxzz.2023-0031
GAO Luyang, LUO Qin, ZHAO Zhihui, ZHAO Qing, LIU Zhihong. Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1060-1066. doi: 10.12290/xhyxzz.2023-0031
Citation: GAO Luyang, LUO Qin, ZHAO Zhihui, ZHAO Qing, LIU Zhihong. Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1060-1066. doi: 10.12290/xhyxzz.2023-0031

球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压新进展

doi: 10.12290/xhyxzz.2023-0031
详细信息
    通讯作者:

    柳志红, E-mail: zhihongliufuwai@163.com

  • 中图分类号: R563;G353.11

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

More Information
  • 摘要: 慢性血栓栓塞性肺动脉高压(chronic thromboembolic pulmonary hypertension, CTEPH)是一种慢性致死性疾病, 由机化的血栓引起肺动脉狭窄或阻塞、血流重新分布以及肺微血管床重构, 导致肺动脉压力和肺血管阻力进行性升高, 最终引发患者右心衰竭甚至死亡。肺动脉血栓内膜剥脱术(pulmonary endarterectomy, PEA)被认为是CTEPH的首选治疗方法, 然而约40%的CTEPH患者由于远端病变或术后出现肺动脉高压无法进行PEA手术。球囊肺动脉成形术(balloon pulmonary angioplasty, BPA)是在血管造影引导下使用合适大小的球囊逐级扩张并打开狭窄或闭塞肺血管的导管介入技术, 可为无法接受PEA手术的CTEPH患者提供新的治疗选择。本文就BPA临床治疗及术后并发症的预测、BPA与PEA联合治疗、BPA与利奥西呱联合治疗等方面的最新研究进展作一综述, 以期为CTEPH患者临床治疗方案的选择提供参考。
    作者贡献:高璐阳负责文献检索及论文撰写;罗勤、赵智慧、赵青负责论文修订;柳志红负责提供论文写作思路。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Mahmud E, Patel M, Ang L, et al. Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Pulm Circ, 2021, 11: 20458940211007385.
    [2] Li X, Zhang Y, Jin Q, et al. Predictors of early response to balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension[J]. Ther Adv Respir Dis, 2022, 16: 17534666221138001.
    [3] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61: 2200879. doi:  10.1183/13993003.00879-2022
    [4] Voorburg JA, Cats VM, Buis B, et al. Balloon angioplasty in the treatment of pulmonary hypertension caused by pulmonary embolism[J]. Chest, 1988, 94: 1249-1253. doi:  10.1378/chest.94.6.1249
    [5] Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension[J]. Circulation, 2001, 103: 10-13. doi:  10.1161/01.CIR.103.1.10
    [6] Kataoka M, Inami T, Hayashida K, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension[J]. Circ Cardiovasc Interv, 2012, 5: 756-762. doi:  10.1161/CIRCINTERVENTIONS.112.971390
    [7] Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension[J]. Circ Cardiovasc Interv, 2012, 5: 748-755. doi:  10.1161/CIRCINTERVENTIONS.112.971077
    [8] Higuchi S, Horinouchi H, Aoki T, et al. Balloon Pulmonary Angioplasty in the Management of Chronic Thromboembolic Pulmonary Hypertension[J]. Radiographics, 2022, 42: 1881-1896. doi:  10.1148/rg.210102
    [9] Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar[J]. J Am Coll Cardiol, 2020, 76: 2155-2169. doi:  10.1016/j.jacc.2020.08.074
    [10] Ogawa A, Satoh T, Fukuda T, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry[J]. Circ Cardiovasc Qual Outcomes, 2017, 10: e004029. doi:  10.1161/CIRCOUTCOMES.117.004029
    [11] Kennedy MK, Kennedy SA, Tan KT, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-analysis[J]. Cardiovasc Intervent Radiol, 2023, 46: 5-18. doi:  10.1007/s00270-022-03323-8
    [12] Brenot P, Jaïs X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53: 1802095. doi:  10.1183/13993003.02095-2018
    [13] Jansa P, Heller S, Svoboda M, et al. Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile[J]. J Clin Med, 2020, 9: 3608. doi:  10.3390/jcm9113608
    [14] Umemoto S, Abe K, Hosokawa K, et al. Increased Pulmonary Arterial Compliance after Balloon Pulmonary Angio-plasty Predicts Exercise Tolerance Improvement in Inoper-able CTEPH Patients with Lower Pulmonary Arterial Pressure[J]. Heart Lung, 2022, 52: 8-15. doi:  10.1016/j.hrtlng.2021.11.003
    [15] Jin Q, Luo Q, Yang T, et al. Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty[J]. Respir Res, 2019, 20: 250. doi:  10.1186/s12931-019-1211-y
    [16] Yamasaki Y, Abe K, Kamitani T, et al. Balloon pulmonary angioplasty improves right atrial reservoir and conduit functions in chronic thromboembolic pulmonary hypertension[J]. Eur Heart J Cardiovasc Imaging, 2020, 21: 855-862. doi:  10.1093/ehjci/jeaa064
    [17] Deng L, Quan R, Yang Y, et al. Characteristics and long-term survival of patients with chronic thromboembolic pulmonary hypertension in China[J]. Respirology, 2021, 26: 196-203.
    [18] Velázquez Martín M, Maneiro Melón N, Albarrán González-Trevilla A, et al. Balloon pulmonary angioplasty can be an effective and safe therapeutic option in non-surgical elderly patients[J]. Front Cardiovasc Med, 2022, 9: 1001518. doi:  10.3389/fcvm.2022.1001518
    [19] Zoppellaro G, Badawy MR, Squizzato A, et al. Balloon Pulmonary Angioplasty in Patients With Chronic Thromboem-bolic Pulmonary Hypertension- A Systematic Review and Meta-Analysis[J]. Circ J, 2019, 83: 1660-1667. doi:  10.1253/circj.CJ-19-0161
    [20] Li X, Zhang Y, Luo Q, et al. Diffusing Capacity for Carbon Monoxide Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension[J]. Front Cardiovasc Med, 2021, 8: 762267. doi:  10.3389/fcvm.2021.762267
    [21] Wang L, Han X, Wang M, et al. Ventilation/perfusion imaging predicts response to balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension[J]. Ann Nucl Med, 2022, 36: 515-522. doi:  10.1007/s12149-022-01731-x
    [22] Kriechbaum SD, Vietheer JM, Wiedenroth CB, et al. Cardiac biomarkers as indicators of right ventricular dysfunction and recovery in chronic thromboembolic pulmonary hypertension patients after balloon pulmonary angioplasty therapy - a cardiac magnetic resonance imaging cohort study[J]. Pulm Circ, 2021, 11: 20458940211056500.
    [23] Oka T, Nakanishi R, Kabuki T, et al. Appropriate Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmon-ary Hypertension Improves Right Ventricular Ejection Fraction via Lung Perfusion Scan[J]. Int Heart J, 2022, 63: 91-98. doi:  10.1536/ihj.21-437
    [24] Zhang Y, Li X, Luo Q, et al. Heart-Rate Recovery at 1 Min After Exercise Predicts Response to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboem-bolic Pulmonary Hypertension[J]. Front Cardiovasc Med, 2022, 9: 795420. doi:  10.3389/fcvm.2022.795420
    [25] Taniguchi Y, Brenot P, Jais X, et al. Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension[J]. Chest, 2018, 154: 521-531. doi:  10.1016/j.chest.2018.03.059
    [26] Hong C, Lu J, Chen R, et al. CXCL10 levels in diagnosis and improved hemodynamics in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty[J]. Pulm Circ, 2022, 12: e12091. doi:  10.1002/pul2.12091
    [27] Lang I, Meyer BC, Ogo T, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension[J]. Eur Respir Rev, 2017, 26: 160119. doi:  10.1183/16000617.0119-2016
    [28] Wiedenroth CB, Deissner H, Adameit MSD, et al. Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome[J]. J Heart Lung Transplant, 2022, 41: 1086-1094. doi:  10.1016/j.healun.2022.05.002
    [29] Inami T, Kataoka M, Shimura N, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty[J]. JACC Cardiovasc Interv, 2013, 6: 725-736. doi:  10.1016/j.jcin.2013.03.009
    [30] Mahmud E, Behnamfar O, Ang L, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension[J]. Interv Cardiol Clin, 2018, 7: 103-117.
    [31] Brenot P, Jaïs X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53: 1802095. doi:  10.1183/13993003.02095-2018
    [32] Rodgers MS, Kirkby LC, Amaral-Almeida L, et al. Acute lung injury after balloon pulmonary angioplasty results in a similar haemodynamic response and possible clinical advantage at follow-up[J]. Pulm Circ, 2022, 12: e12166. doi:  10.1002/pul2.12166
    [33] Dieplinger B, Mueller T. Soluble ST2 in heart failure[J]. Clin Chim Acta, 2015, 443: 57-70. doi:  10.1016/j.cca.2014.09.021
    [34] Banaszkiewicz M, Pietrasik A, Florczyk M, et al. Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty[J]. Diagnostics (Basel), 2021, 11: 133. doi:  10.3390/diagnostics11010133
    [35] Ikeda N, Kubota S, Okazaki T, et al. The predictors of complications in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Catheter Cardiovasc Interv, 2019, 93: E349-E356.
    [36] Asano R, Ogo T, Ohta-Ogo K, et al. Prolonged QRS duration as a predictor of right ventricular dysfunction after balloon pulmonary angioplasty[J]. Int J Cardiol, 2019, 280: 176-181. doi:  10.1016/j.ijcard.2018.11.026
    [37] Tsukada J, Yamada Y, Kawakami T, et al. Treatment effect prediction using CT after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension[J]. Eur Radiol, 2021, 31: 5524-5532. doi:  10.1007/s00330-021-07711-5
    [38] Palazzini M, Saia F, Taglieri N, et al. Balloon pulmonary angioplasty after pulmonary thromboendarterectomy[J]. Ann Cardiothorac Surg, 2022, 11: 192-194. doi:  10.21037/acs-2021-pte-19
    [39] Zhang L, Bai Y, Yan P, et al. Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a syste-matic review and meta-analysis[J]. Heart Fail Rev, 2021, 26: 897-917. doi:  10.1007/s10741-020-10070-w
    [40] Martin-Suarez S, Loforte A, Cavalli GG, et al. Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team[J]. Ann Cardiothorac Surg, 2022, 11: 120-127. doi:  10.21037/acs-2021-pte-23
    [41] Kawashima T, Yoshitake A, Kawakami T, et al. Two-stage Treatment Using Balloon Pulmonary Angioplasty and Pulmonary Endarterectomy in a Patient with Chronic Thromboembolic Pulmonary Hypertension[J]. Ann Vasc Surg, 2018, 49: 315.e5-315.e7. doi:  10.1016/j.avsg.2017.11.057
    [42] Atas H, Mutlu B, Akaslan D, et al. Balloon Pulmonary Angioplasty in Patients With Inoperable or Recurrent/Residual Chronic Thromboembolic Pulmonary Hypertension: A Single-Centre Initial Experience[J]. Heart Lung Circ, 2022, 31: 520-529. doi:  10.1016/j.hlc.2021.10.009
    [43] Andersen A, Hansen JV, Dragsbaek SJ, et al. Balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension previously operated by pulmonary endarterectomy[J]. Pulm Circ, 2022, 12: e12115. doi:  10.1002/pul2.12115
    [44] Kataoka M, Inami T, Kawakami T, et al. Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hyperten-sion: A Japanese Perspective[J]. JACC Cardiovasc Interv, 2019, 12: 1382-1388. doi:  10.1016/j.jcin.2019.01.237
    [45] Phan K, Jo HE, Xu J, et al. Medical Therapy Versus Balloon Angioplasty for CTEPH: A Systematic Review and Meta-Analysis[J]. Heart Lung Circ, 2018, 27: 89-98. doi:  10.1016/j.hlc.2017.01.016
    [46] Wang W, Wen L, Song Z, et al. Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis[J]. Clin Cardiol, 2019, 42: 741-752. doi:  10.1002/clc.23212
    [47] Kalra R, Duval S, Thenappan T, et al. Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hyperten-sion: A Systematic Review and Meta-Analysis[J]. Sci Rep, 2020, 10: 8870. doi:  10.1038/s41598-020-65697-4
    [48] Kawakami T, Matsubara H, Shinke T, et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial[J]. Lancet Respir Med, 2022, 10: 949-960. doi:  10.1016/S2213-2600(22)00171-0
    [49] Aoki T, Sugimura K, Terui Y, et al. Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty - A randomized controlled study[J]. Int J Cardiol Heart Vasc, 2020, 29: 100579.
    [50] Minatsuki S, Hatano M, Kiyosue A, et al. Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty[J]. Int Heart J, 2018, 59: 1186-1188. doi:  10.1536/ihj.17-660
    [51] Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension[J]. Pulm Circ, 2018, 8: 2045894018783996.
    [52] Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study[J]. Lancet Respir Med, 2022, 10: 961-971. doi:  10.1016/S2213-2600(22)00214-4
  • 加载中
计量
  • 文章访问数:  143
  • HTML全文浏览量:  49
  • PDF下载量:  48
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-01-12
  • 录用日期:  2023-02-09
  • 刊出日期:  2023-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!